Last deal

$60M

Amount

Series D

Stage

19.03.2014

Date

3

all rounds

$146M

Total amount

date founded

Financing round

General

About Company
Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Series D

IPO status

Private

Description

Kolltan Pharmaceuticals is a clinical-stage enterprise that focuses on discovering and developing drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), and KTN0158, a monoclonal antibody targeting KIT. Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. The company is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
F-Star Therapeutics

F-Star Therapeutics

F-Star Therapeutics is a biopharmaceutical company that develops novel bispecific antibody products to improve the current standard of care.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, UK

total rounds

8

total raised

$137.29M
Cend Therapeutics Inc.

Cend Therapeutics Inc.

Cend Therapeutics Inc. develops cancer therapies that overcome drug delivery barriers to solid tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

La Jolla, San Diego, CA, USA

total rounds

2

total raised

$3.1M
Innate Pharma

Innate Pharma

Innate Pharma S.A. is a global biotech company that develops therapeutic antibodies to fight cancer by harnessing the immune system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Marseille, France

total rounds

8

total raised

$314.54M
Peloton Therapeutics

Peloton Therapeutics

Peloton Therapeutics is a biopharmaceutical company developing cancer drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Dallas, TX, USA

total rounds

4

total raised

$242.6M
M&A Details
1

Acquired by

Celldex Therapeutics

announced date

01.11.2016

price

$235M

Financials

Funding Rounds
6
3

Number of Funding Rounds

$146M

Money Raised

Their latest funding was raised on 19.03.2014. Their latest investor Purdue Pharma. Their latest round Series D

OUP (Osage University Partners)

OUP (Osage University Partners)

Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups commercializing university research.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Education

Location

Bala Cynwyd, PA, USA

count Of Investments

155

count Of Exists

28
Purdue Pharma

Purdue Pharma

Purdue Pharma is a private company that develops, manufactures and markets medications and consumer health products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Stamford, CT, USA

total rounds

1

total raised

$1.8M

count Of Investments

6

count Of Exists

1
HBM Healthcare Investments AG

HBM Healthcare Investments AG

HBM Healthcare Investments finances companies in the medical and biotech sectors.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Medical, Biotechnology, Venture Capital

Location

Zug, Switzerland

count Of Investments

204

count Of Exists

32
Deerfield

Deerfield

Deerfield is an investment management firm that specializes in healthcare investments, including information, investment, and philanthropy.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

New York, NY, USA

total rounds

1

total raised

$25M

count Of Investments

193

count Of Exists

36
Fidelity

Fidelity

Fidelity is a privately-owned investment manager that offers a wide range of financial services.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Boston, MA, USA

total rounds

11

total raised

$166.33M

count Of Investments

139

count Of Exists

24
KLP Enterprises

KLP Enterprises

In Q2 2022, the company did not have any founders.

Sector

General Industrials

Subsector

Diversified Industrials

Location

North Haven, CT 06473, USA

count Of Investments

5

count Of Exists

3
HBM Healthcare Investments AG

HBM Healthcare Investments AG

HBM Healthcare Investments finances companies in the medical and biotech sectors.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Medical, Biotechnology, Venture Capital

Location

Zug, Switzerland

count Of Investments

204

count Of Exists

32
Co-Investors
Investors
9
8

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series A, Series D
Yes
Series A
Yes
Series C, Series D
Purdue Pharma

Purdue Pharma

Purdue Pharma is a private company that develops, manufactures and markets medications and consumer health products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Stamford, CT, USA

total rounds

1

total raised

$1.8M

count Of Investments

6

count Of Exists

1
Elm Street Ventures

Elm Street Ventures

ESVC creates life sciences companies from Yale University's intellectual property and other regional research institutions.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Venture Capital, Biotechnology, Financial Services

Location

New Haven, CT, USA

count Of Investments

25

count Of Exists

8
HBM Healthcare Investments AG

HBM Healthcare Investments AG

HBM Healthcare Investments finances companies in the medical and biotech sectors.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Medical, Biotechnology, Venture Capital

Location

Zug, Switzerland

count Of Investments

204

count Of Exists

32

People

Founders
3
Arthur Altschul Jr.
Arthur Altschul Jr.

Arthur Altschul Jr.

Arthur G. Altschul, Jr., is the co-Founder of Kolltan and Chairman of Kolltan's Board of Directors. Mr. Altschul has worked in money management, investment banking and as a member of senior management of a publicly-traded health care concern. He is a founder of Diaz & Altschul Capital Management, LLC, a private investment advisory firm. Between 1985 and 1991, Mr. Altschul worked, variously, at Goldman, Sachs & Co., The Maximus Fund, LP and Morgan Stanley & Co. From its founding in 1992 through 1996, Mr. Altschul worked at SUGEN, Inc., a biopharmaceutical company focused on cancer drug development, which is now owned by Pfizer, Inc. Mr. Altschul serves on the board of directors of General American Investors, Inc. (NYSE: GAM), a publicly-traded closed-end investment company with over $1 billion in gross assets and Medicis Pharmaceutical Corporation (NYSE: MRX), the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Mr. Altschul is a director of The Overbrook Foundation, a trustee of The Neurosciences Research Foundation, and a director of the Child Mind Institute. Mr. Altschul received his B.Sc. in Computer Science from Columbia University.

current job

Diaz & Altschul Capital Management

organization founded

3

Arthur Altschul Jr.

Joseph Schlessinger
Joseph Schlessinger

Joseph Schlessinger

Joseph Schlessinger is the co-Founder of Kolltan, a member of Kolltan's Board of Directors and Chairman of Kolltan's Scientific Advisory Board. Schlessinger is the Chairman of the Department of Pharmacology and the William Prusoff Professor at Yale School of Medicine and the Director of the Cancer Biology Institute of Yale University. From 1990 to 2001, he was Chairman of the Department of Pharmacology and the Helen and Milton A. Kimmelman Professor at New York University Langone Medical Center. He was also the director of the Skirball Institute of NYU from 1998 until 2001. Before co-founding Kolltan, he co-founded SUGEN, Inc. in 1991 and in 2001 he co-founded Plexxikon. He was also the chairman of Plexxikon's Board of Directors and a member of Plexxikon's Scientific Advisory Board from 2001 until 2011. From 1980 to 1991, Schlessinger was the Ruth and Leonard Simon Professor in Cancer Research in the Department of Chemical Immunology at the Weizmann Institute of Science, Rehovot, Israel. Schlessinger was research director at Rorer Biotechnology, Inc. in Pennsylvania from 1988 to 1990. He has also held positions at Meloy Laboratories, Inc. in Rockville, Maryland from 1985 to 1988. Schlessinger has authored or co-authored more than 475 scientific articles and papers focusing on signal transduction, growth control mechanisms, receptor structure functions and the biophysics of proteins. He is a member of the National Academy of Science, a fellow of the American Academy of Arts and Sciences, a member of the Institute of Medicine at the National Academies, a member of the European Academy of Science, and a foreign member of the Russian Academy of Sciences. He is on the editorial boards of Cell, Molecular Cell, and the Journal of Cellular Biology as well as many other journals. Schlessinger's academic honors include the Drew Ciba Prize, the Antoine Lacassagne Prize, the Dan David Prize, the Distinguished Service Award of Miami Biotechnology, an Honorary Membership of the Japanese Biochemical Society, Honorary Doctor of Philosophy from the University of Haifa, the Medal of Danica Hrvatska Order from the Republic of Croatia and the Penzcoller-AACR International Award for Cancer among many others. He presented the E.J. Cohn Lecture at Harvard Medical School, the Edmond Fischer Lecture at the University of Geneva, the Lamport Lecture at the University of Seattle, the Harvey Lecture at Rockefeller University, the Opening Keynote Lecture at the American Society for Biochemistry and Molecular Biology annual meeting, the NIH Director Lecture, the Distinguished Lecture on Molecular Targets for Cancer Prevention at the AACR in Baltimore, Maryland, the NIH-WALS Lecture in Bethesda, Maryland and the Twenty-fourth Medical Scientist Lecture Series at UC Irvine, the Ef Racker Lecture in Biology and Medicine, at Cornell university as well as numerous others. Schlessinger received his B.Sc., Magna Cum Laude, in chemistry and physics and his M.Sc., Magna Cum Laude, in chemistry from the Hebrew University in Jerusalem, Israel. He received his Ph.D. from the Department of Chemical Physics at the Weizmann Institute in Rehovot, Israel in the field of biophysics.

current job

Plexxikon
Plexxikon

organization founded

3

Joseph Schlessinger

Lawrence Fritz
Lawrence Fritz

Lawrence Fritz

Lawrence C. Fritz is a successful biotechnology entrepreneur with over 25 years of experience in the industry. Prior to joining Auspex he was Founder, President and CEO of Covella Pharmaceuticals, a company focused on inflammatory diseases. Covella was acquired in 2010 by Santarus, Inc. Prior to Covella, he founded Conforma Therapeutics and served as its President and CEO from inception through its acquisition by Biogen Idec in 2006. Conforma focused on the discovery and development of novel small-molecule drugs for cancer therapy. Fritz was also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma; Cabrellis was subsequently acquired by Pharmion Corporation. Prior to Conforma, Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. In addition to his work in private biotechnology companies, Fritz served as President and CEO of Anadys Pharmaceuticals, a NASDAQ-listed public company developing drugs for viral diseases and oncology. Fritz is also an Entrepreneur-in-Residence with the venture capital firm Thomas, McNerney & Partners. He holds an A.B. in Biochemical Sciences from Harvard, an M.Sc. in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.

current job

Kolltan Pharmaceuticals
Kolltan Pharmaceuticals

organization founded

2

Lawrence Fritz

Employee Profiles
28
Keith Darragh

Keith Darragh

Vice President of Finance & Administration and Treasurer

Carolyn F. Sidor

Carolyn F. Sidor

Senior Vice President of Clinical and Regulatory Affairs & Chief Medical Officer

Ed Natoli

Scientist, department of bioprocess development

Lawrence Fritz

Lawrence Fritz

Executive Chairman, Co-Founder

Yaron Hadari

Yaron Hadari

Vice President of Research

Gerald McMahon

Gerald McMahon

President & CEO

Carmela Senese

Executive assistant to president and ceo, svpchief financial and business officer

Stanley Choy

Stanley Choy

Finance Executive and Business Leader

Activity

Recent News
0